新辅助化疗及间歇性减瘤术后HIPEC与铂耐药或难治性疾病相关
单中心回顾性比较2010—2019年接受新辅助化疗(NACT)及间歇性减瘤术(IDS)的晚期高级别浆液性卵巢癌患者,其中20例加用HIPEC、48例未用。HIPEC组铂难治进展或铂耐药复发风险显著升高(50% vs 23%;RR=2.18;95%CI 1.11,4.30;P=0.024),无进展生存与全因死亡率无差异。
要点
- HIPEC组铂难治或耐药复发风险更高(RR=2.18;95%CI 1.11,4.30;P=0.024)。
- HIPEC组3/4级术后并发症更多(65% vs 4%),住院时间更长(8 vs 5天)。
- 两组中位无进展生存(11.5 vs 12个月)与全因死亡率(19.1 vs 30.5个月)无差异。
核心结论
- 在晚期高级别浆液性卵巢癌接受NACT和IDS的患者中,HIPEC与铂难治或耐药性疾病风险增加相关。
- HIPEC组手术复杂度更高,可能带来更高的并发症率,但未改善肿瘤学结局。
研究设计与样本
- 单中心回顾性研究,纳入2010至2019年接受NACT及IDS的晚期高级别浆液性卵巢癌患者,HIPEC组20例、非HIPEC组48例。
- 比较两组临床病理信息与结局。
主要发现
- HIPEC组与非HIPEC组平均年龄分别为62岁与60岁,IV期比例均为40%。
- HIPEC组完全减瘤率95% vs 50%,平均手术时间530 vs 216分钟。
- HIPEC组3/4级术后并发症65% vs 4%,平均住院8 vs 5天。
- HIPEC组铂难治进展或铂耐药复发50% vs 23%(RR=2.18;95%CI 1.11,4.30;P=0.024)。
- 中位无进展生存11.5 vs 12个月、全因死亡率19.1 vs 30.5个月,两组无差异。
关键数值与推荐
- 铂难治进展或铂耐药复发:HIPEC组50%,非HIPEC组23%,RR=2.18(95%CI 1.11,4.30),P=0.024。
- 完全减瘤率:HIPEC组95%,非HIPEC组50%。
- 3/4级术后并发症:HIPEC组65%,非HIPEC组4%。
临床怎么用
- 对接受NACT和IDS的晚期高级别浆液性卵巢癌患者,选择HIPEC需权衡更高的铂耐药风险与并发症率。
- HIPEC不宜作为默认方案,应结合手术复杂度与患者获益个体化决策。
局限性
- 单中心回顾性设计,样本量小(HIPEC组20例、非HIPEC组48例),可能存在选择偏倚。
- 作者指出需进一步研究与长期随访评估HIPEC在晚期卵巢癌初始治疗中的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe our single-institution oncologic outcomes of patients who received neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: We compared clinicopathologic information and outcomes for all patients with advanced stage, high-grade serous ovarian cancer who received NACT and IDS with (N = 20) or without (N = 48) HIPEC at our institution from 2010 to 2019 RESULTS: Mean age (62 years with HIPEC and 60 years without HIPEC) and proportion of stage 4 disease (40% for both) did not differ between cohorts. HIPEC patients had higher rates of complete cytoreduction (95% vs 50%), longer mean duration of surgery (530 vs. 216 min), more grade 3 or 4 postoperative complications (65% vs. 4%), and longer mean length of hospital stay (8 vs. 5 days). HIPEC patients had significantly higher risk for platinum-refractory progression or platinum-resistance recurrence (50% vs 23%; RR = 2.18; 95% CI 1.11, 4.30, p = 0.024). Median progression free survival (11.5 vs. 12 months) and all-cause mortality (19.1 vs. 30.5 months) in the HIPEC and non-HIPEC cohorts, respectively, did not differ CONCLUSIONS: HIPEC was associated with increased risk for platinum refractory or resistant disease. Higher surgical complexity may contribute to higher complication rates without improving oncologic outcomes in our patients. Further investigations and long-term follow-up are needed to assess the utility of HIPEC in primary treatment of advanced stage ovarian cancer.
引用
- Jou J, Zimmer Z, Charo L, et al. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease. Gynecol Oncol. 2020. PMID: 33293046. doi:10.1016/j.ygyno.2020.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。